NHL33

An ALLG Window Study of Acalabrutinib plus Rituximab followed by Cytarabine, Oxaliplatin, Dexamethasone and Rutixumab (R-DHAOx) + Autologous Stem Cell Transplant (ASCT) in newly diagnosed fit Mantle Cell Lymphoma patients.

Menu